Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
Immunome’s Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock in an open-market transaction on April 2, 2026, according to an SEC Form 4 filing.
The transaction value was based on the SEC Form 4 reported price of $21.64 per share. The post-transaction value was based on the April 2, 2026 market close price of $21.84.
The filing also notes that 6,291 shares gifted on March 30, 2026 are excluded from the share counts, transaction values, and post-transaction balances referenced above.
The sale reduced Higgins’s direct holdings by 30.02%, from 31,438 shares to 22,000 shares.
Higgins’s indirect holdings attributed to his children’s custodial accounts were not affected by this transaction and remain at 3,000 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which the filing context indicates supports the view that the transaction was routine liquidity management rather than discretionary market timing.
In the available EDGAR filing history, one prior open-market sale was identified: 3,524 shares sold on August 15, 2024. The April 2, 2026 sale of 9,438 shares is approximately 2.7 times larger than that earlier transaction.
Immunome is a clinical-stage biotechnology company focused on antibody therapeutics for oncology and infectious diseases. Its lead programs include IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2. The company’s research-driven model aims to discover and advance proprietary antibody-based therapies for unmet needs.
Because the sale was tied to a Rule 10b5-1 plan set up in December 2025 for financial diversification, the transaction timing and price were established months in advance. After the sale, Higgins remained substantially invested, with a direct position valued at roughly $480,000 at the April 2 close.
For investors, the filing context emphasizes that company-specific milestones may be more informative than a pre-planned executive sale. The article highlights varegacestat’s Phase 3 RINGSIDE trial hitting its primary endpoint in December 2025, with an NDA submission planned for Q2 2026, alongside early data from IM-1021 and three IND submissions expected across 2026.

Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…